Prime Capital Investment Advisors LLC Has $10.41 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Prime Capital Investment Advisors LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,676 shares of the medical research company’s stock after selling 6,928 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $10,411,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMO. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific in the first quarter worth $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $31,000. IMA Advisory Services Inc. bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMO has been the subject of several recent research reports. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Finally, Barclays lifted their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $585.37.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $543.88 on Monday. The company has a market capitalization of $205.38 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a 50-day simple moving average of $482.58 and a 200 day simple moving average of $446.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.